Clarithromycin Triple Therapy Plus Bismuth for Helicobacter Pylori First-line Treatment
Status:
Completed
Trial end date:
2017-09-30
Target enrollment:
Participant gender:
Summary
Standard triple therapy including a proton pump inhibitor (PPI) and clarithromycin with
either amoxicillin or metronidazole are no longer recommended as empirical first-line therapy
to treat Helicobacter pylori infection because of high antibiotic resistance. It is unknown
whether the addition of bismuth overcome antibiotic resistance. This study is designed to
evaluate the efficacy and safety of the addition of bismuth to standard triple therapy for H.
pylori first-line eradication.